AURX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AURX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Nuo Therapeutics's Average Total Inventories for the three months ended in Dec. 2024 was $0.16 Mil. Nuo Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.09 Mil. Hence, Nuo Therapeutics's Days Inventory for the three months ended in Dec. 2024 was 166.77.
The historical rank and industry rank for Nuo Therapeutics's Days Inventory or its related term are showing as below:
During the past 13 years, Nuo Therapeutics's highest Days Inventory was 4610.53. The lowest was 17.73. And the median was 80.04.
Nuo Therapeutics's Days Inventory declined from Dec. 2023 (467.38) to Dec. 2024 (166.77).
Inventory Turnover measures how fast the company turns over its inventory within a year. Nuo Therapeutics's Inventory Turnover for the three months ended in Dec. 2024 was 0.55.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Nuo Therapeutics's Inventory-to-Revenue for the three months ended in Dec. 2024 was 0.40.
The historical data trend for Nuo Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | 4,610.53 | 646.65 | 216.83 |
Nuo Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
467.38 | 376.63 | 295.87 | 173.92 | 166.77 |
For the Biotechnology subindustry, Nuo Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Nuo Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as
Days Inventory (A: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2023 ) | + | Total Inventories (A: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2024 ) | * | Days in Period |
= | ( (0.21 | + | 0.15) | / | 2 ) | / | 0.303 | * | 365 |
= | 0.18 | / | 0.303 | * | 365 | ||||
= | 216.83 |
Nuo Therapeutics's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:
Days Inventory (Q: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2024 ) | + | Total Inventories (Q: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | ( (0.168 | + | 0.15) | / | 2 ) | / | 0.087 | * | 365 / 4 |
= | 0.159 | / | 0.087 | * | 365 / 4 | ||||
= | 166.77 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (OTCPK:AURX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Nuo Therapeutics's Inventory Turnover for the three months ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0.087 | / | 0.159 | |
= | 0.55 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nuo Therapeutics's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0.159 | / | 0.395 | |
= | 0.40 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Nuo Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles E Sheedy | 10 percent owner | TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010 |
David Emerson Jorden | director, officer: CEO, CFO | 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381 |
Lawrence Atinsky | director | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
C Eric Winzer | director | |
Paul Mintz | director | C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877 |
Peter Clausen | officer: CSO | 11204 JEFFRO COURT, IJAMSVILLE MD 21754 |
Scott M. Pittman | director | 3683 JOHN NASH BLVD., BLUEFIELD WV 24701 |
Boyalife Investment Fund I, Inc. | 10 percent owner | 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616 |
Dean Tozer | officer: CHIEF COMMERCIAL OFFICER | C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880 |
Steven A Shallcross | officer: SEE REMARKS | C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4 |
Aldagen Holdings, Llc | 10 percent owner, other: May be part of a 13(d) group | C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607 |
Kathryne Carr | 10 percent owner, other: May be part of a 13(d) group | 315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903 |
William W Brooke | 10 percent owner, other: May be part of a 13(d) group | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
Guercio Joseph Del | director | C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814 |
B. Jefferson Clark | 10 percent owner, other: May be part of a 13(d) group | C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713 |
From GuruFocus
By GuruFocus News • 04-17-2025
By PRNewswire PRNewswire • 10-07-2020
By PRNewswire PRNewswire • 03-22-2019
By PRNewswire PRNewswire • 01-16-2019
By Marketwired • 04-17-2025
By PRNewswire PRNewswire • 04-20-2021
By Marketwired • 06-22-2023
By Marketwired • 06-26-2023
By Ds*** Ds*** • 08-30-2022
By GlobeNewswire GlobeNewswire • 02-04-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.